Condition

SARS-CoV-2

ClinicalTrials.gov condition label

Clinical trials8

Recruiting0

Common interventions16

Lead sponsors shown8

Clinical trials

8 shown

Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)NCT05435027 · 2022-02-28

Anxiety, Depression and Eating Attitudes of Diabetes Mellitus Patients During COVID-19 Lockdown in GreeceNCT04700254 · 2020-12-28

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).NCT04433546 · 2020-07-15

Advanced Endoscopy During COVID-19NCT04385147 · 2020-05-18

Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune DiseaseNCT04345159 · 2020-04-17

COVID-19 in Patients With HIVNCT04333953 · 2020-04-01

Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.NCT04345315 · 2020-03-27

Hemodynamic Characteristics of Patients With SARS-CoV-2NCT04337983 · 2020-03-13

Common interventions

DASS questionnaireOTHER1 EAT-26 questionnaireOTHER1 EchocardiographyDEVICE1 Endoscopic management according to standard of careOTHER1 GRT-R912, samRNA-Spikebeta-TCE11DRUG1 GRT-R914, samRNA-Spikebeta-TCE9DRUG1 GRT-R918, samRNA-SpikeOmicron-N-TCE11DRUG1 Low Dose (10 mg) ControlDRUG1 Next generation Sequencing (NGS) analysisGENETIC1 No interventionOTHER1 Pemziviptadil (PB1046)DRUG1 Questionnaire by phone callOTHER1 Rapid molecular testOTHER1 serological testOTHER1 serum chemistry analysisOTHER1 Transpulmonary thermodilutionDEVICE1

Leading sponsors

Al-Azhar University1 Bicetre Hospital1 Chania General Hospital "St. George"1 Fondation Ophtalmologique Adolphe de Rothschild1 Gritstone bio, Inc.1 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1 PhaseBio Pharmaceuticals Inc.1 University of Missouri-Columbia1

Trial status mix

COMPLETED6

TERMINATED1

UNKNOWN1

Phase mix

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.